FUJIFILM RI Pharma

Fujifilm RI Pharma was a leading Japanese specialist in radiopharmaceuticals, focusing on the development, manufacture, and distribution of nuclear medicine products. Originally established in 1968 as Daiichi Radioisotope Laboratories, it became a subsidiary of Fujifilm in 2006 before merging with Toyama Chemical in 2018 to create Fujifilm Toyama Chemical. The company provided a wide range of diagnostic imaging agents for SPECT and PET scans, particularly in the fields of oncology, cardiology, and neurology. Key products in its portfolio included DaTSCAN for Parkinson's disease and Vizamyl for Alzheimer's disease imaging. Fujifilm RI Pharma was known for its sophisticated manufacturing facilities capable of handling radioisotopes with short half-lives. Its business model integrated research and development with specialized logistics to support clinical sites across Japan.